Maintaining ERBB Blockade in EGFR-mutated Lung Cancer

Summary

This study aims to compare the efficacy of afatinib maintenance with pemetrexed maintenance following induction therapy with platinum/ pemetrexed in patients with metastatic epidermal growth factor receptor (EGFR) mutated non-small-cell lung cancer (NSCLC) progressing after first-line treatment with afatinib with respect to progression-free survival.

Timeline

Start

2015-11

Primary completion

2017-12

Completion

2017-12

Drugs

Indications